CMV Clinical Trial - Effect of Atorvastatin on Subclinical Atherosclerosis

Status Enrolling by invitation

Clinical Trial Summary

Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect. Its pleiotropic properties also adding beneficial effect against CMV infection.

The investigators plan to study atorvastatin in virally- suppressed HIV-infected patients on stable ART with CMV seropositive and statin-naïve to evaluate the subclinical atherosclerosis changes assessed by carotid intima media thickness (CIMT).

Clinical Trial Description

Extended description of the protocol, including more technical information ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04101136
Study type	Interventional
Source	Dr Cipto Mangunkusumo General Hospital
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	September 30, 2019
Completion date	July 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06001320` - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip	Early Phase 1
Completed	`NCT01923766` - Cytotoxic T Cells to Prevent Virus Infections	Phase 1
Not yet recruiting	`NCT05969743` - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease	Phase 2
Recruiting	`NCT01011712` - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting	`NCT06034925` - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients	Phase 4
Completed	`NCT04840199` - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.	Phase 2
Terminated	`NCT03502161` - Clinical Evaluation of the QuantiFERON CMV Assay
Not yet recruiting	`NCT06211543` - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting	`NCT04056533` - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy	Phase 2
Not yet recruiting	`NCT04280380` - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting	`NCT03924219` - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Not yet recruiting	`NCT06453460` - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla	Phase 2
Completed	`NCT02694484` - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant	N/A
Recruiting	`NCT06011486` - Expansion of Virus-Specific Lymphocytes for Cell Therapy	Phase 1
Recruiting	`NCT04017962` - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection	Phase 2
Terminated	`NCT03570411` - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Enrolling by invitation	`NCT04392297` - Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Completed	`NCT00872703` - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?	N/A
Active, not recruiting	`NCT01945814` - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)	Phase 1
Recruiting	`NCT05041426` - Letermovir for CMV Prevention After Lung Transplantation	Phase 2